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Introduction: The objective of this study was to determine whether 
the addition of ramucirumab to first-line paclitaxel–carboplatin che-
motherapy in patients with advanced non–small-cell lung cancer 
(NSCLC) resulted in a 6-month progression-free survival (PFS) rate 
that compares favorably with the historic rate for bevacizumab com-
bined with paclitaxel–carboplatin in this patient population.
Methods: In this phase II, single-arm, open-label, multicenter study, 
40 patients with advanced NSCLC received ramucirumab (10 mg/kg 
intravenous [IV]) followed by paclitaxel (200 mg/m2 IV) and carbopla-
tin area under the curve = 6 on day 1 every 21 days as first-line therapy. 
Therapy continued for up to six cycles. Patients not experiencing with-
drawal criteria may have continued ramucirumab monotherapy every 3 
weeks. The primary endpoint was PFS at 6 months, with 80% power to 
detect a 6-month PFS rate of at least 55%.
Results: The 6-month PFS rate was 59.0% and the objective response 
rate was 55.0%. The most common treatment-related adverse events 
were fatigue, peripheral neuropathy, nausea, epistaxis, and myalgia. 
Single-nucleotide polymorphism (SNP) rs2981582 on the FGFR-2 
gene had significant associations with improved overall survival, 
PFS, and best overall response (p values without multiplicity adjust-
ment were 0.0059, 0.0429, and 0.0392, respectively).
Conclusion: Ramucirumab in combination with paclitaxel–carbopl-
atin resulted in a 6-month PFS rate and safety profile that compared 
favorably with the historical control. In addition, no deaths were 
associated with this treatment. Furthermore, we describe an associa-
tion of SNP on FGFR-2 gene with survival and response. These find-
ings warrant further clinical investigation in patients with NSCLC.
Key Words: Angiogenesis, Lung cancer, Ramucirumab, Paclitaxel, 
Carboplatin.
(J Thorac Oncol. 2014;9: 1532–1539)
Angiogenesis, the formation of new capillaries and blood vessels, is a tightly controlled, multistep process that is a 
component of normal human physiology, including develop-
ment of the embryonic vasculature, wound healing, and tissue 
repair. Pathologic angiogenesis contributes to tumor growth and 
metastasis, and other human diseases such as diabetic retinopa-
thy, rheumatoid arthritis, and psoriasis.1–3 The importance of vas-
cular endothelial growth factor (VEGF) and vascular endothelial 
growth factor receptor-2 (VEGFR-2) in angiogenesis and tumor 
growth has been demonstrated in a variety of animal models, in 
which disabling the function of the VEGF/VEGFR-2 pathway 
inhibited new blood vessel formation and tumor growth.4–7
VEGF and VEGFR-2 are overexpressed in the majority 
of human cancers, including carcinomas of the gastrointestinal 
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tract, pancreas, breast, cervix, bladder, ovary, uterus, endo-
metrium, kidney, and lung.6 VEGFR-2 expression and tumor 
microvessel density have been associated with poor prognosis, 
advanced disease, increased risk of metastasis and recurrence, 
and lower progression-free survival (PFS) in multiple types of 
cancers, including non–small-cell lung cancer (NSCLC).2,6,7
Therapeutic agents that interfere with the function of 
VEGF and its receptors may be efficacious antitumor therapy. 
Antitumor effects have been demonstrated by disabling the 
function of the VEGFR-2 signaling pathway using anti-VEGF 
antibodies and small molecule VEGFR-2 tyrosine kinase 
inhibitors (TKIs) in a variety of animal models.
The addition of antiangiogenic therapy (anti-VEGF: beva-
cizumab) to cytotoxic chemotherapy in treatment-naïve patients 
with advanced NSCLC in Eastern Cooperative Oncology Group 
(ECOG) Study Trial-E4599 was shown to improve survival.8
Ramucirumab is a human immunoglobulin G, subclass 
1 monoclonal antibody that specifically binds to the extracel-
lular domain of VEGFR-2 with high affinity.9 This antibody 
blocks the binding of the VEGF ligand to VEGFR-2, inhib-
its VEGF-stimulated activation of both VEGFR-2 and p44/
p42 MAP kinases, and neutralizes VEGF-induced endothelial 
cells’ proliferation and migration.9
Two completed phase I studies of ramucirumab have 
evaluated pharmacokinetics and demonstrated safety and toler-
ability at clinically relevant doses, with preliminary evidence of 
clinical efficacy.10,11 In these studies, 62 patients with advanced 
cancer received ramucirumab either weekly, every other week, or 
every third week at doses ranging from 2 to 20 mg/kg. Objective 
antitumor activity and antiangiogenic effects were observed 
over a wide range of dose levels, suggesting that ramucirumab 
may have a favorable therapeutic index in treating malignancies 
amenable to VEGFR-2 inhibition. Furthermore, ramucirumab 
has been approved by the US Food and Drug Administration 
in gastric cancer following progression on initial chemotherapy 
based on the positive results of a phase III study.12
This phase II trial was conducted to assess whether the 
addition of ramucirumab to combination therapy with pacli-
taxel and carboplatin results in favorable PFS in patients with 
advanced NSCLC compared with historical controls.
PATIENTS AND METHODS
Eligibility Criteria
Patients greater than or equal to 18 years with ECOG 
performance status (PS) of 0 to 1 and histologically or cyto-
logically confirmed, measurable, stage IIIB or IV NSCLC 
were eligible. American Joint Committee on Cancer (AJCC) 
sixth edition was used for staging derivation. Eligibility criteria 
included adequate hepatic, renal, hematologic, and coagulation 
function. Patients with untreated central nervous system metas-
tases were excluded. Other exclusion criteria included prior sys-
temic chemotherapy for stage IIIB/IV NSCLC, prior systemic 
chemotherapy or radiation therapy for stage I–IIIA NSCLC less 
than 1 year before the first dose of study medication, prior beva-
cizumab therapy, evidence of major blood vessel invasion or 
encasement by cancer, uncontrolled thrombotic or hemorrhagic 
disorders, serious nonhealing wounds, or grade 3 to 4 gastroin-
testinal bleeding within 3 months before study entry.
Study Design
This was a phase II, single-arm, multicenter, open-label 
study of combination therapy of ramucirumab with paclitaxel 
and carboplatin in patients with advanced NSCLC conducted 
at eight centers in the United States. The primary objective of 
the study was to evaluate the 6-month PFS rate. Secondary 
objectives included PFS, overall survival (OS), objective 
response rate (ORR), safety/tolerability, and the pharmaco-
kinetic profile of ramucirumab, in addition to an exploratory 
analysis of potential biomarkers in tumor tissue and their 
potential association with clinical outcomes.
Each center’s institutional review board or ethics com-
mittee approved the protocol. This study was conducted in 
accordance with good clinical practices and International 
Conference on Harmonisation (ICH) guidelines as imple-
mented in the European Union and Japanese guidelines, and 
any other regional/national requirements for clinical trials, as 
applicable. Patients provided written informed consent before 
undergoing study procedures or receiving study treatment.
Treatment and Dose Adjustments
Patients received ramucirumab 10 mg/kg via IV infu-
sion over 1 hour on day 1 of each 21-day cycle (i.e., every 3 
weeks). Study combination treatment continued for up to six 
cycles (each cycle consisting of 1 infusion of each medica-
tion on day 1 of a 3-week period), or until there was evidence 
of disease progression or intolerable toxicity. In the absence 
of any withdrawal criteria, patients completing combination 
therapy could continue to receive ramucirumab monotherapy 
every 3 weeks, provided there was ongoing evidence of clini-
cal benefit.
Patients received paclitaxel 200 mg/m2 via IV infusion 
over 3 hours on day 1 following the ramucirumab infusion. 
Before each infusion of paclitaxel, patients were premedicated 
with an oral steroid (such as dexamethasone 20 mg adminis-
tered 6 and 12 hours before paclitaxel [or IV equivalent]), 
an antihistamine (H1 antagonist), and an antiemetic (such 
as cimetidine [300 mg IV]). Patients received carboplatin on 
day 1 after paclitaxel as an IV infusion over 30 minutes. The 
target area under the curve (AUC) for carboplatin treatment 
was AUC = 6, unless the dose was modified. The creatinine 
clearance used to calculate the carboplatin dose was estimated 
based on serum creatinine, using the modified Calvert for-
mula. Antiemetics (a 5-HT3 receptor antagonist or equiva-
lent) were given in conjunction with carboplatin and therapy; 
corticosteroids were given prophylactically before carboplatin 
administration and continued for 72 hours.
Doses were modified for ramucirumab-related infusion 
reactions, hypertension, thrombotic events, and proteinuria; 
paclitaxel hypersensitivity reactions; and carboplatin treat-
ment-related events. In addition, doses of paclitaxel and/or 
carboplatin were reduced (by 20–25%) or held in the pres-
ence of certain hematologic and nonhematologic toxicities. If 
a second episode of certain events occurred or if the event 
resolved, chemotherapy was readministered at a reduced dose 
(30–50%). If the dose of chemotherapy was reduced, sub-
sequent dose increases were not permitted. Events causing 
ramucirumab discontinuation were occurrence of greater than 
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2 g/24 hours proteinuria, or a protein level that did not return 
to less than 2 g/24 hours within 2 weeks; grade 3/4 hyperten-
sion, bleeding or hemorrhagic event, arterial thrombotic, or 
venous thrombotic event considered by the investigator to be 
life-threatening or symptomatic and not adequately treated, or 
infusion reaction; grade 4 pulmonary embolism; or hemopty-
sis that exceeded the severity grade present at study entry. A 
grade greater than or equal to 1 central nervous system hem-
orrhage required all three drugs to be discontinued. If ramu-
cirumab was permanently discontinued, then therapy with 
the other study agents continued and the patient remained on 
study; if carboplatin or paclitaxel was permanently discontin-
ued, all study treatments were discontinued and the patient 
was discontinued from the study.
Safety and Efficacy Assessments
Evaluations done at baseline and each cycle included 
physical examination, vital signs, ECOG PS, and hematology 
and chemistry profiles. Adverse events (AEs) were catego-
rized and graded at each cycle according to National Cancer 
Institute Common Terminology Criteria for Adverse Events 
(CTCAE), version 3.0.
Patients were evaluated for response according to 
Response Evaluation Criteria in Solid Tumors v1.0 guidelines 
using serial tumor assessments at baseline and every 6 weeks 
(i.e., every two cycles) from the start of the first dose of study 
medication. Imaging studies included computed tomography 
scan or magnetic resonance imaging of the chest and upper 
abdomen (including both adrenal glands).
Pharmacokinetic Assessments
During cycles 1 to 6, blood samples were collected from 
all patients before infusion and 1 hour after the conclusion 
of the infusion. The samples were analyzed for ramucirumab 
using a validated Enzyme Linked Immunosorbent Assay 
method (Intertek Pharmaceutical Services, San Diego, CA). 
These data were summarized using Phoenix WinNonlin 6.3. 
For the purposes of data summaries, all values below the 
quantifiable lower limit of the assay were treated as missing.
Serum Biomarker Assays
Serum samples were obtained from patients for analy-
sis of potential biomarkers. The following analytes were 
assayed on samples collected at baseline using assay kits from 
Mesoscale Discovery (MSD): HGF, TNF-alpha, IL1-beta, 
IL-6, IL-8, Thrombomodulin, E-Selectin, P-Selectin, sICAM3, 
KDR, PIGF, Tie-2, VEGF-A, VEGF-C, VEGF-D, bFGF, and 
sFLT-1. The various analytes were measured using non-GLP 
quantitative sandwich electrochemiluminescence kits manu-
factured by MSD.
Single-Nucleotide Polymorphisms
In total, 21 individual single-nucleotide polymorphisms 
(SNPs) were assessed for germline mutations in whole blood 
samples from the following genes (with number of SNPs per 
gene in parentheses): VEGFR-2 (3), NOS3 (1), VEGF-A (5), 
NRP1 (1), ICAM1 (2), HIF1a (1), NOS1 (eNOS) (1), SDF-1a 
(1), IL-8 (1), CXCR1 (1), FCGR2a (1), FCGR3A (1), FGFR-2 
(1), and HIF1 (1).
Copy Number Variant-Fluorescence 
In Situ Hybridization Assay
The following genes were assessed for copy number 
variants (CNVs) in formalin-fixed, paraffin-embedded (FFPE) 
tissue sections using the fluorescence in situ hybridization 
(FISH) assay: FGFR-1, VEGF-A, VEGFR-1, and VEGFR-
2. Signals were enumerated in at least 50 interphase nuclei 
per specimen. For each gene, several patient-level summaries 
were reported, including the mean copy number per cell (con-
tinuous measurement), mean score (ordinal measure derived 
from the mean), and percentage score (based on the percent-
age of cells displaying less than or equal to 2, 3, or greater 
than or equal to 4 copies of the gene signal).
Data and Statistical Analyses
The sample size was calculated based on the histori-
cal data from a randomized phase III study of bevacizumab 
in combination with paclitaxel and carboplatin as first-line 
therapy demonstrating a 6-month PFS rate of 55% in first-
line NSCLC patients. A 6-month PFS rate of at least 55% 
was considered acceptable, whereas a 6-month PFS rate of 
35% or lower was of no interest. A 6-month PFS rate between 
these outcomes was equivocal. This sample size provided 
80% power to demonstrate the assumed 6-month PFS rate at 
a 5% significance level. Based on this, the current study was 
designed to enroll approximately 40 patients.
Efficacy and safety analyses were performed on all 
patients who provided informed consent and received any 
quantity of study medication using SAS version 8.2 or later 
(SAS Institute, Cary, NC), or comparable software.
For exploratory analyses involving correlation of bio-
markers with efficacy (OS, PFS, and best overall response 
[BOR]), biomarkers were used as covariates in statistical 
models as follows. Cox proportional hazard models and 
logistic regression models were used for time-to-event and 
binary efficacy outcomes, respectively.13 For serum biomark-
ers, if greater than 20% of the samples were below the limits 
of quantitation, then the biomarkers were treated as binary 
covariates dichotomized at the upper/lower limit of quantita-
tion. Otherwise, they were treated separately as (1) continu-
ous covariates and (2) continuous covariates, treated as binary 
with automatic cut-point selection using applicable maxi-
mal χ2 technique.14 Since most patients in the intent-to-treat 
population were non-Hispanic whites, for correlative analy-
ses of SNPs with clinical outcomes, the analysis population 
was restricted to non-Hispanic white patients who had SNPs 
assayed. For serum biomarkers and CNV data, the analysis 
populations consisted of all patients who had the assay types 
performed. Standard quality control filtering methods were 
applied to SNPs before testing for association with clinical 
outcomes.
In general, usage of the genotypic model was not feasible 
for SNPs due to low cell counts for the rare homozygote group. 
However, the two genes of primary interest (i.e., VEGF-A and 
VEGFR-2) had SNPs with reasonable representation within 
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each genotype group. Hence, SNPs in VEGF-A or VEGFR-2  
that passed quality control were tested under the genotypic 
model (ternary variables). All SNPs (including those in 
VEGF-A and VEGFR-2) were also modeled as presence ver-
sus absence of the minor allele (binary variables). All analyses 
relating CNV-FISH to clinical endpoints were done using both 
the patients’ mean signals and the patients’ percentage score. 
No multiplicity correction was applied other than in the use of 
maximal χ2 and in the correlative analyses of SNPs (this was 
done within individual endpoints using the method to control 
false discovery rate and q values were reported along with the 
individual p values).14,15
RESULTS
Patient Characteristics and Treatment
The first patient was enrolled in January 2009 and 
the last patient completed treatment in January 2012. Of 
41 patients enrolled, 40 received study treatment and were 
included in all analyses. Table 1 lists baseline demographics 
and disease characteristics. The median age was 59.5 years 
(range, 35–78 years). The majority of patients were female (25 
patients, 62.5%), white (34 patients, 85.0%), had an ECOG 
PS of 1 (25 patients, 62.5%), tumor histology of adenocarci-
noma (34 patients, 85.0%), and stage IV disease (33 patients, 
82.5%) at baseline. Lungs (39 patients, 97.5%) and lymph 
nodes (24 patients, 60.0%) were the most common sites of 
metastasis. Smoking status and tumor EGFR or KRAS muta-
tion status were not collected on this study.
Dose Administration
Thirty-two patients received all doses of ramucirumab 
at greater than or equal to 90% of the planned 10-mg/kg dose 
level. The median duration of ramucirumab therapy was 24.4 
weeks (range, 3.0–95.1) and the median number of ramuci-
rumab infusions was 8.0 (range, 1–31). The mean cumula-
tive ramucirumab dose was 94.51 mg/kg (standard deviation 
[SD] = 63.630 mg/kg, range, 10.2–320.3 mg/kg) and the 
mean relative dose intensity was 94.9% (SD = 7.6%, range, 
65.9–105.0%). Supplemental Figure 1 (Supplemental Digital 
Content, http://links.lww.com/JTO/A640) presents the dura-
tion of study drug exposure. A total of 26 patients (65.0%) 
received ramucirumab monotherapy subsequent to discon-
tinuation of paclitaxel and carboplatin (13 discontinued due 
to AEs). There were no ramucirumab dose reductions; seven 
patients had dose omissions.
The median duration of paclitaxel therapy was 18.0 
weeks (range, 6.0–22.1) and the median number of pacli-
taxel infusions was 6.0 (range, 2–6). The mean cumulative 
paclitaxel dose was 926.06 mg/m2 (SD = 293.144 mg/m2, 
range, 224.7–1300.0 mg/m2) and the mean relative dose inten-
sity was 88.9% (SD = 13.4%, range, 56.2–106.6%). Twelve 
patients had paclitaxel dose reductions and 12 patients had 
dose omissions.
The median duration of carboplatin therapy was 18.0 
weeks (range, 6.0–22.1) and the median number of carbo-
platin infusions was 6.0 (range, 2–6). The mean cumulative 
carboplatin dose was 3363.47 mg (SD = 1225.492 mg, range, 
958.0–5601.0 mg) and the mean relative dose intensity was 
93.0% (SD = 17.9%, range, 49.2–133.4%). Nine patients 
had carboplatin dose reductions and 10 patients had dose 
omissions.
Efficacy
The PFS rate at 6 months derived from Kaplan–Meier 
analysis was 59.0% (95% confidence interval [CI]: 41.3–
72.9%). A total of 15 patients (37.5%) had disease progres-
sion within 6 months from the start of study treatment. The 
TABLE 1.  Key Demographics and Characteristics at Baseline
Parameter
Ramucirumab + Paclitaxel + 
Carboplatin, n = 40
Sex, n (%)
  Male 15 (37.5)
  Female 25 (62.5)
Race, n (%)
  Asian 2 (5.0)
  Black or African American 4 (10.0)
  White 34 (85.0)
Ethnicity, n (%)
  Hispanic or Latino 3 (7.5)
  Non-Hispanic or Latino 37 (92.5)
Age, years
  Mean (SD) 59.1 (10.22)
  Median 59.5
  Min–Max 35–78
ECOG PS, n (%)
  0 15 (37.5)
  1 25 (62.5)
Current staging at enrollment, n (%)
  IIIB 6 (15.0)
  IV 33 (82.5)
  Missinga 1 (2.5)
Histology/cytology, n (%)
  Adenocarcinoma 34 (85.0)
  Large cell 2 (5.0)
  Squamous 1 (2.5)
  Other histology 3 (7.5)
Site of metastatic disease, n (%)
  Lung 39 (97.5)
  Lymph node 24 (60.0)
  Pleura 18 (45.0)
  Bone 15 (37.5)
Previous therapy, n (%)
  Chemotherapy 5 (12.5)
  Hormonal therapy 1 (2.5)
  Immunotherapy 2 (5.0)
  Radiotherapy 13 (32.5)
Previous surgery, n (%) 34 (85.0)
aThe baseline staging for this patient was IIIB.
ECOG PS, Eastern Cooperative Oncology Group performance status; Min, 
minimum; Max, maximum; SD, standard deviation.
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median Kaplan–Meier estimate of PFS was 7.85 months 
(95% CI: 5.49–9.86 months; Fig. 1A). The median OS time 
was 16.85 months (95% CI: 14.82–28.58 months; Fig. 1B). Of 
the 40 patients treated, 26 had died at the time of data cutoff 
date (January 6, 2012). The ORR was 55.0% (95% CI: 38.5–
70.7%; Table 2). One patient (2.5%) had a complete response 
(CR) and 21 patients (52.5%) had a partial response (PR). The 
disease control rate (CR + PR + stable disease) was 90.0% 
(95% CI: 76.3–97.2%). Fig. 2 shows a waterfall plot of best 
overall percent change from baseline of target lesion measure-
ments for treated patients.
Safety
A total of 34 patients (85.0%) experienced treatment-
emergent adverse events (TEAEs) considered related to ramu-
cirumab. Most treatment-related TEAEs were CTCAE grade 
2 or 3. The most common treatment-related TEAEs (of all 
grades) were fatigue (21 patients, 52.5%), peripheral neurop-
athy (13 patients, 32.5%), nausea (11 patients, 27.5%), and 
epistaxis and myalgia (9 patients each, 22.5%). Ten patients 
(25.0%) experienced a grade 3 treatment-related TEAE and 
five patients (12.5%) experienced a grade 4 treatment-related 
TEAE. Neutropenia (four patients, 10.0%), thrombocytopenia 
and fatigue (three patients each, 7.5%), and peripheral neu-
ropathy (two patients, 5.0%) were the most frequently reported 
grade 3 treatment-related TEAEs (Table 3). No grade 3 or 
above hemoptysis was reported in this study. Febrile neutro-
penia and pulmonary embolism (two patients each, 5.0%) and 
neutropenia and thrombocytopenia (one patient each, 2.5%) 
were the only grade 4 TEAEs related to treatment (Table 3).
Eight patients (20.0%) experienced serious adverse 
events (SAEs) considered related to treatment. Febrile neu-
tropenia (grade 4) was reported by two patients (5.0%); the 
remaining related SAEs were reported by one patient each. 
Thirteen patients discontinued ramucirumab treatment due to 
AEs. The most frequently reported AEs (two patients each, 
5%) leading to discontinuation were infusion-related reaction 
(not related to ramucirumab), neutropenia (one incident was 
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FIGURE 1.  Kaplan–Meier estimates for PFS (A) and OS (B). CI, confidence interval; mo, months; OS, overall survival; PFS, 
progression-free survival.
TABLE 2.  Best Overall Response
Ramucirumab + Paclitaxel + 
Carboplatin, n = 40
Best response, n (%)
  CR 1 (2.5)
  PR 21 (52.5)
  SD 14 (35.0)
  Progressive disease 3 (7.5)
  Not evaluablea 1 (2.5)
Objective response rate (CR + PR), % 55.0
  95% CI (exact) (38.5–70.7)
Disease control rate (CR + PR + SD), % 90.0
  95% CI (exact) (76.3–97.2)
aNot evaluable due to missing scans.
CI, confidence interval; CR, complete response; PR, partial response; SD, stable 
disease.
FIGURE 2.  Waterfall plot of best overall percent change 
from baseline in target lesion measurement (n = 39).
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not related to ramucirumab), and fatigue. The majority of AEs 
leading to ramucirumab discontinuation occurred within the 
first six cycles of treatment. No patients died during the study 
or within 30 days of the last dose of study medication.
Pharmacokinetics
Ramucirumab concentration–time data were available 
for 39 NSCLC patients. Concentrations at 1-hour postend of 
infusion appeared to be stabilized after the third infusion, with 
geometric mean (coefficient of variation [CV%]) values rang-
ing from 365 μg/ml (21%) to 394 μg/ml (31%) between cycle 
4 and cycle 6. Greater interindividual variability was observed 
for trough concentrations relative to concentrations obtained 
at 1-hour postend of infusion. The geometric means (CV%) of 
trough concentration ranged from 36.8 μg/ml (100%) to 73.6 
μg/ml (60%) between cycle 4 and cycle 6.
Biomarker Analysis
To ensure that a relatively homogenous group of 
patients was analyzed for mutational differences with respect 
to the clinical outcomes of interest, the correlative analyses 
of SNPs with clinical outcomes were restricted to the non-
Hispanic white patients who had SNPs assayed. Different 
translational research populations were considered for each 
assay platform: SNPs (restricted to non-Hispanic whites [n = 
22]), serum biomarkers (n = 23), and FISH-CNV (n = 23). 
The SNP results from one patient in the translational research 
population were excluded from the analysis due to failing the 
quality control criteria, reducing this group to 21 patients. 
Notably, SNP rs2981582 on the FGFR-2 gene had significant 
associations (without multiplicity adjustment) with all three 
clinical outcomes (Figs. 3A–C); unadjusted p values for tests 
of association with OS, PFS, and BOR were, respectively, 
0.0059, 0.0429, and 0.0392 and false discovery rate q values 
for tests of association of that SNP with OS, PFS, and BOR 
were, respectively, 0.1000, 0.4838, and 0.3580.
High IL-6 serum levels had significant associations with 
both decreased PFS and OS (p values from maximal χ2 anal-
yses of 0.0038 and 0.0029, respectively), but not with BOR 
(p = 0.2883) (data not shown).
Correlative analyses of CNV-FISH data with clinical 
endpoints did not yield any significant (5% level) findings.
DISCUSSION
The ECOG 4599 study demonstrated that the combina-
tion of bevacizumab with paclitaxel-carboplatin chemotherapy 
resulted in a survival benefit (median OS of 12.3 months in 
the bevacizumab-containing arm compared with 10.3 months 
in the chemotherapy-alone arm).8 However, there were more 
treatment-related deaths in the bevacizumab-containing arm. 
In this single-arm phase II study, the addition of ramucirumab 
to a standard, platinum-based chemotherapy regimen resulted 
in comparable PFS with promising OS and acceptable safety. 
The 6-month PFS rate was 59.0%, with a median PFS of 7.85 
months, a median ORR of 55.0%, and a clinical benefit rate 
(CR + PR + stable disease) of 90.0%. The median OS was 
16.85 months. The effects of ramucirumab on survival and 
PFS were consistent with the ECOG 4599 study, in which the 
addition of bevacizumab improved median PFS to 6.2 months, 
compared with 4.5 months with chemotherapy alone.8
Ramucirumab was administered every 3 weeks as a 
10 mg/kg IV infusion. Exposure appeared to be stabilized 
after the third infusion. Medium to large interindividual vari-
ability was observed for trough concentrations.
There were no unexpected toxicities, and AEs were 
within the acceptable range when compared with the ECOG 
4599 study.8 A total of 34 patients experienced TEAEs consid-
ered related to study medication, with the majority of events 
being CTCAE grade 2 or 3. Eight patients (20.0%) experi-
enced SAEs considered related to treatment. No grade 3 or 
above hemoptysis was reported in this study. Whereas most 
AEs are similar to those observed with bevacizumab,8 it is 
notable that within this study, no patients died during the study 
or within 30 days of the last dose of study medication.
Recently, genomic analyses have led to advances in 
the treatment of lung adenocarcinoma and improvements in 
patients’ outcomes. Examples include the use of EGFR inhibi-
tors, such as gefitinib and erlotinib for lung adenocarcinoma 
bearing EGFR mutation, and ALK inhibitors, such as crizotinib 
for ALK translocations.16–19 Other approaches include studies of 
cytokine expression profiles and association with clinical out-
comes in NSCLC. Similar to our findings, Koh and colleagues 
found that prognosis for patients with increased IL-6 expression 
was worse than for patients with lower IL-6 expression.20
In our biomarker analysis, SNP rs2981582 on the 
FGFR-2 gene had significant associations (without multi-
plicity adjustment) with all three clinical outcomes. FGFR-
2 amplification, mutations, and germline SNP have been 
associated with clinical outcomes in several human cancers, 
including gastric, endometrial, and breast cancer.21 For exam-
ple, FGFR-2 has been identified as a breast cancer suscepti-
bility gene and SNPs located in the second intron of FGFR-2 
TABLE 3.  Adverse Events Possibly, Probably, or Definitely 
Related to Treatment
Eventa
Ramucirumab + Paclitaxel + Carboplatin, n = 40
All Grades, 
n (%)
Grade 3, 
n (%)
Grade 4, 
n (%)
Grade 5, 
n (%)
Thrombocytopenia 8 (20.0) 3 (7.5) 1 (2.5) 0
Neutropenia 6 (15.0) 4 (10.0) 1 (2.5) 0
Febrile neutropenia 3 (7.5) 1 (2.5) 2 (5.0) 0
Anemia 2 (5.0) 1 (2.5) 0 0
Constipation 5 (12.5) 1 (2.5) 0 0
Fatigue 21 (52.5) 3 (7.5) 0 0
Anorexia 7 (17.5) 1 (2.5) 0 0
Peripheral neuropathy 13 (32.5) 2 (5.0) 0 0
Dyspnea on exertion 2 (5.0) 1 (2.5) 0 0
Pulmonary embolism 2 (5.0) 0 2 (5.0) 0
Hypertension 5 (12.5) 1 (2.5) 0 0
aIncludes those events graded 3, 4, or 5, with their respective all grades total. At 
each level of summarization, a patient is counted once according to the TEAE with worst 
grade. One patient is counted for each TEAE when several events are reported for the 
same patient.
TEAE, treatment-emergent adverse event.
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were found to correlate with an increased risk of developing 
breast cancer. SNP rs2981582 in FGFR-2 was shown to be 
associated with breast cancer risk for BRCA1 and 2 carriers 
with ER-positive breast cancer.22 Meyer and colleagues23 have 
shown that SNP rs2981582 is associated with higher level of 
FGFR-2 transcription, both in cell lines and in tumors. The 
SNP is located in the transcription factor binding sites (C/
EBPb and Oct-1/Runx2) and could affect the binding effi-
ciency of these factors. Genome-wide analysis of ER binding 
sites has revealed three potential ER binding sites within the 
FGFR-2 gene,24 and ER and Oct-1/Runx2 may cooperate to 
increase gene expression. The disease-associated genotype of 
SNP rs2981582 in FGFR-2 may also depend on the signaling 
potential of FGFR-2 in ER-positive cells. One mechanism 
by which elevated levels of FGFR-2 may contribute to the 
establishment of an autocrine signaling loop is by reducing 
the cell’s propensity to undergo apoptosis.25 To our knowl-
edge, this has not yet been shown in NSCLC. Mouse models 
have confirmed that fibroblast growth factor (FGF) signal-
ing has oncogenic potential, including roles in angiogenesis, 
but have also importantly demonstrated that FGF signaling 
can have tumor suppressive function.21 Since the biological 
effect (if any) of this intronic SNP in FGFR-2 is not clear, it 
is not possible to speculate on why it appears associated with 
clinical benefit within this study. In addition, as the study was 
not randomized, it is not possible to attribute any effect to 
prognostic as opposed to potential predictive associations. 
Finally, if predictive, it is not possible to ascribe the effect to 
any specific component of the three-drug combination given 
to these patients. The association with clinical benefit was 
consistent across three separate measures of clinical benefit 
(OS, PFS, and response), albeit without strict control for mul-
tiple testing; hence, this biomarker is a potential candidate 
for further exploration in the future. In addition, a lack of 
information of the EGFR mutation status and smoking sta-
tus limits conclusions for this study population. However, 
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FIGURE 3.  Biomarker analysis and association with clinical outcomes: association of SNP rs2981582 G/G and A/G or A/A 
with PFS (A), OS (B), and best overall response rate (C) in treated non-Hispanic Caucasian patients in the translational research 
population with SNP data (n = 21). The median and upper ends of the 95% CI for OS in the patients with A/G or A/A genotype 
were not estimable. CI, confidence interval; NE, nonestimable; OS, overall survival; PFS, progression-free survival; SNP, single-
nucleotide polymorphism.
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ramucirumab appeared to be well tolerated with encouraging 
signs of efficacy, and with a potential biomarker to investigate 
in additional detail, further development of this compound in 
front-line NSCLC should be considered.
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